Potent high-avidity neutralizing antibodies and T-cell responses after COVID-19 vaccination in patients with B-cell lymphoma and multiple myeloma. Keppler-Hafkemeyer et al.

Name: Potent high-avidity neutralizing antibodies and T-cell responses after COVID-19 vaccination in patients with B-cell lymphoma and multiple myeloma. Keppler-Hafkemeyer et al.
Creator: Paul Wratil
Published: 2022-11-18T22:00:03.877Z
Keywords: Severe Acute Respiratory Syndrome Coronavirus 2

Wratil, Paul

doi:10.17632/z6dw96y8sw.1

Potent high-avidity neutralizing antibodies and T-cell responses after COVID-19 vaccination in patients with B-cell lymphoma and multiple myeloma. Keppler-Hafkemeyer et al.

Published: 18 November 2022| Version 1 | DOI: 10.17632/z6dw96y8sw.1

Contributor:

Paul Wratil

Description

Pseudonymized patient record data as well as raw data from antibody, avidity, and live-virus neutralization measurements in patients with hematopoietic neoplasia and healthy donors.

Files

Institutions

Ludwig-Maximilians-Universitat Munchen

Potent high-avidity neutralizing antibodies and T-cell responses after COVID-19 vaccination in patients with B-cell lymphoma and multiple myeloma. Keppler-Hafkemeyer et al.

Description

Files

Institutions

Categories

Licence